Many genetic drivers of prostate cancer were also prominent, such as mutations and deletions of TP53 and PTEN, MYC amplifications and alterations in DNA damage repair pathways, including germline and somatic BRCA2 loss. This evidence concerns the gene PTEN and prostate carcinoma.